FMP
Nov 10, 2024 12:00 PM - Andrew Wynn(Last modified: Nov 11, 2024 8:13 AM)
Image credit: Google Images
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biopharmaceutical company that focuses on developing protein therapeutics for cancer and autoimmune disorders. The company uses its proprietary XpressCF+ platform for drug discovery, development, and manufacturing. Sutro's leading product candidates, STRO-001 and STRO-002, are currently in Phase 1 clinical trials targeting various cancers.
The consensus price target for Sutro Biopharma has shown a slight increase over the last quarter, moving from $12 to $13. This suggests a modestly positive outlook from analysts, possibly due to developments in their clinical trials or strategic partnerships with companies like Merck and Celgene Corporation. These partnerships are crucial for advancing research in cancer and autoimmune disorders.
Despite the positive sentiment, analysts predict a decline in earnings for Sutro Biopharma in its upcoming financial report. However, the company recently reported impressive quarterly earnings of $0.42 per share, significantly surpassing the Zacks Consensus Estimate, which anticipated a loss of $0.82 per share. This marks a substantial improvement from the previous year's loss of $0.61 per share.
Analyst Edward Tenthoff from Piper Sandler has set a price target of $16 for Sutro Biopharma, indicating a more optimistic view of the company's future performance. Investors should be prepared for these key expectations as they assess the company's financial performance and keep an eye on clinical trial results and partnership developments for potential impacts on the stock's future performance.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...
May 27, 2024 3:30 PM - Rajnish Katharotiya
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...